Kuckma VION - 500 Beiträge pro Seite
eröffnet am 21.10.03 21:27:00 von
neuester Beitrag 24.05.04 20:00:23 von
neuester Beitrag 24.05.04 20:00:23 von
Beiträge: 10
ID: 788.229
ID: 788.229
Aufrufe heute: 0
Gesamt: 592
Gesamt: 592
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 5986 | |
| heute 20:29 | 5729 | |
| vor 1 Stunde | 5625 | |
| heute 20:59 | 4060 | |
| vor 1 Stunde | 4000 | |
| vor 51 Minuten | 3735 | |
| vor 58 Minuten | 3657 | |
| vor 1 Stunde | 3260 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.724,00 | +0,21 | 186 | |||
| 2. | 4. | 6,5390 | -2,72 | 81 | |||
| 3. | 14. | 22,210 | -19,73 | 73 | |||
| 4. | 18. | 31,51 | +6,45 | 69 | |||
| 5. | 6. | 10,710 | +2,19 | 66 | |||
| 6. | 10. | 16,750 | +4,69 | 47 | |||
| 7. | 5. | 177,51 | +1,53 | 47 | |||
| 8. | 3. | 4,4000 | -5,17 | 42 |
Feedback
Mein Kursziel erstmal 4 Euro "kurzfristig", weiter kann ich nicht planen ...
Meinungen ?
Meinungen ?
Dow Jones Business News
Vion Pharma in License Pact With Beijing Pason
Tuesday October 21, 11:02 am ET
NEW HAVEN, Conn. (Dow Jones)--Vion Pharmaceuticals Inc. has entered into a license agreement with Beijing Pason Pharmaceuticals, Inc. related to Vion`s Triapine drug.
In a press release, the company said granted Beijing Pason the exclusive rights to develop, manufacture and market Triapine for anticancer and antiviral uses in China, Taiwan, Hong Kong and Macao. It said the agreement requires final approval from various government agencies in China.
The terms of the agreement include an initial payment of $500,000 on receipt of required approvals, $4.75 million in additional milestone payments, and royalty payments of 11% of any Triapine revenues in this territory. Pason will fund the preclinical and clinical development necessary for regulatory approval of Triapine in this area.
According to Chinese health officials, there are 1 million people infected with human immunodeficiency virus (HIV), 20 million chronic hepatitis B patents and 4.5 million cancer patients. As well, 2 million new cancer patients are diagnosed every year.
Vion is a biopharmaceutical company developing novel agents for the treatment of cancer.
Company Web Site: http://www.vionpharma.com
-------------------------------------------------
Vion Licenses Triapine(R) Rights in China, Taiwan, Hong Kong and Macao
Tuesday October 21, 8:45 am ET
NEW HAVEN, Conn., Oct. 21 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION - News) announced today that the Company had entered into a license agreement with Beijing Pason Pharmaceuticals, Inc. ("Pason") related to the exclusive rights to develop, manufacture and market Triapine® for anticancer and antiviral uses in the mainland of the People`s Republic of China, Taiwan, Hong Kong and Macao (the "Territory"). The agreement awaits final approval from various government agencies of the People`s Republic of China.
ADVERTISEMENT
The terms of the agreement include an initial payment of $500,000 upon receipt of required approvals, $4.75 million in additional milestone payments, and royalty payments of 11% of any Triapine® revenues in the Territory. Pason will fund the preclinical and clinical development necessary for regulatory approval of Triapine® in the Territory.
According to the Ministry of Public Health of the People`s Republic of China (MPH-PRC) and the Chinese Pharmaceutical Association (CPA), China has 1 million people infected with human immunodeficiency virus (HIV) (source: MPH- PRC), 20 million chronic hepatitis B (HBV) patents (source: MPH-PRC), and a total of 4.5 million cancer patients (source: CPA). In addition, 2 million new cancer patients are diagnosed every year (source: CPA). China spends nearly $1 billion on anti-cancer drugs (source: CPA) and $6 billion on anti-HBV medication (source: MPH-PRC) each year.
Alan Kessman, Chief Executive Officer of Vion, said, "We are pleased to be in partnership with Pason to commercialize Triapine® in China, Taiwan, Hong Kong and Macao. The potential markets in these regions for the treatment of cancer and viral disease are substantial."
Dr. Sen Liu, the Chief Executive Officer of Beijing Pason Pharmaceuticals said, "We believe that Pason`s license of Triapine® is among the first such technology transfers in the pharmaceutical industry in China since its entrance into the World Trade Organization." He added, "We are glad to collaborate with Vion to develop Triapine® in China. It is our belief that, by licensing patents and new technology, China`s pharmaceutical companies will be able to develop high quality chemical drugs more effectively. Collaborations with foreign companies will improve our product pipeline, and in the long run, benefit patients."
Vion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel agents for the treatment of cancer. Vion`s portfolio of agents includes: Triapine®, a potent inhibitor of a key step in DNA synthesis; VNP40101M, a unique DNA alkylating agent; and TAPET®, a modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its research and product development programs, visit the company`s Internet web site at www.vionpharm.com.
Beijing Pason Pharmaceuticals, Inc. ("Pason") is a pharmaceutical company focused on the development of anti-cancer and anti-HBV drugs. Pason`s products include: BP9906, an anti-HBV agent and BP-Inter 014, an anti-cancer agent. Pason also has a subsidiary that specializes in developing and distributing diagnostic products for infectious diseases. For more information, visit www.pason-pharm.com.
------------------------------
USW:
Fri, Oct 17, 2003
• Peregrine`s Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At The American Association For Cancer Research Meeting
Fri, Oct 17 - 10:59am ET - PR Newswire
Thu, Oct 16, 2003
• Peregrine Pharma 2C3 Study: Developing Pdt For Humans
Thu, Oct 16 - 1:30pm ET - Dow Jones Business News
• Peregrine`s Anti-Angiogenesis 2C3 Anti-VEGF Antibody Presented at American Association For Cancer Research Meeting
Thu, Oct 16 - 11:42am ET - PR Newswire
Tue, Oct 14, 2003
• Peregrine Reports Voting Results Of Annual Meeting
Tue, Oct 14 - 2:14pm ET - PR Newswire
Tue, Sep 30, 2003
• Peregrine Pharma/Tumor Agent: Sees Human Trials In `04
Tue, Sep 30 - 1:12pm ET - Dow Jones Business News
• Peregrine`s Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At Angiogenesis Conference
Tue, Sep 30 - 12:04pm ET - PR Newswire
Thu, Sep 18, 2003
• Peregrine Pharmaceuticals Financials
Thu, Sep 18 - 10:02am ET - EDGAR Online Financials
• Targeted Delivery of Tissue Factor Research Published in `Cancer Research`
Vion Pharma in License Pact With Beijing Pason
Tuesday October 21, 11:02 am ET
NEW HAVEN, Conn. (Dow Jones)--Vion Pharmaceuticals Inc. has entered into a license agreement with Beijing Pason Pharmaceuticals, Inc. related to Vion`s Triapine drug.
In a press release, the company said granted Beijing Pason the exclusive rights to develop, manufacture and market Triapine for anticancer and antiviral uses in China, Taiwan, Hong Kong and Macao. It said the agreement requires final approval from various government agencies in China.
The terms of the agreement include an initial payment of $500,000 on receipt of required approvals, $4.75 million in additional milestone payments, and royalty payments of 11% of any Triapine revenues in this territory. Pason will fund the preclinical and clinical development necessary for regulatory approval of Triapine in this area.
According to Chinese health officials, there are 1 million people infected with human immunodeficiency virus (HIV), 20 million chronic hepatitis B patents and 4.5 million cancer patients. As well, 2 million new cancer patients are diagnosed every year.
Vion is a biopharmaceutical company developing novel agents for the treatment of cancer.
Company Web Site: http://www.vionpharma.com
-------------------------------------------------
Vion Licenses Triapine(R) Rights in China, Taiwan, Hong Kong and Macao
Tuesday October 21, 8:45 am ET
NEW HAVEN, Conn., Oct. 21 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION - News) announced today that the Company had entered into a license agreement with Beijing Pason Pharmaceuticals, Inc. ("Pason") related to the exclusive rights to develop, manufacture and market Triapine® for anticancer and antiviral uses in the mainland of the People`s Republic of China, Taiwan, Hong Kong and Macao (the "Territory"). The agreement awaits final approval from various government agencies of the People`s Republic of China.
ADVERTISEMENT
The terms of the agreement include an initial payment of $500,000 upon receipt of required approvals, $4.75 million in additional milestone payments, and royalty payments of 11% of any Triapine® revenues in the Territory. Pason will fund the preclinical and clinical development necessary for regulatory approval of Triapine® in the Territory.
According to the Ministry of Public Health of the People`s Republic of China (MPH-PRC) and the Chinese Pharmaceutical Association (CPA), China has 1 million people infected with human immunodeficiency virus (HIV) (source: MPH- PRC), 20 million chronic hepatitis B (HBV) patents (source: MPH-PRC), and a total of 4.5 million cancer patients (source: CPA). In addition, 2 million new cancer patients are diagnosed every year (source: CPA). China spends nearly $1 billion on anti-cancer drugs (source: CPA) and $6 billion on anti-HBV medication (source: MPH-PRC) each year.
Alan Kessman, Chief Executive Officer of Vion, said, "We are pleased to be in partnership with Pason to commercialize Triapine® in China, Taiwan, Hong Kong and Macao. The potential markets in these regions for the treatment of cancer and viral disease are substantial."
Dr. Sen Liu, the Chief Executive Officer of Beijing Pason Pharmaceuticals said, "We believe that Pason`s license of Triapine® is among the first such technology transfers in the pharmaceutical industry in China since its entrance into the World Trade Organization." He added, "We are glad to collaborate with Vion to develop Triapine® in China. It is our belief that, by licensing patents and new technology, China`s pharmaceutical companies will be able to develop high quality chemical drugs more effectively. Collaborations with foreign companies will improve our product pipeline, and in the long run, benefit patients."
Vion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel agents for the treatment of cancer. Vion`s portfolio of agents includes: Triapine®, a potent inhibitor of a key step in DNA synthesis; VNP40101M, a unique DNA alkylating agent; and TAPET®, a modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its research and product development programs, visit the company`s Internet web site at www.vionpharm.com.
Beijing Pason Pharmaceuticals, Inc. ("Pason") is a pharmaceutical company focused on the development of anti-cancer and anti-HBV drugs. Pason`s products include: BP9906, an anti-HBV agent and BP-Inter 014, an anti-cancer agent. Pason also has a subsidiary that specializes in developing and distributing diagnostic products for infectious diseases. For more information, visit www.pason-pharm.com.
------------------------------
USW:
Fri, Oct 17, 2003
• Peregrine`s Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At The American Association For Cancer Research Meeting
Fri, Oct 17 - 10:59am ET - PR Newswire
Thu, Oct 16, 2003
• Peregrine Pharma 2C3 Study: Developing Pdt For Humans
Thu, Oct 16 - 1:30pm ET - Dow Jones Business News
• Peregrine`s Anti-Angiogenesis 2C3 Anti-VEGF Antibody Presented at American Association For Cancer Research Meeting
Thu, Oct 16 - 11:42am ET - PR Newswire
Tue, Oct 14, 2003
• Peregrine Reports Voting Results Of Annual Meeting
Tue, Oct 14 - 2:14pm ET - PR Newswire
Tue, Sep 30, 2003
• Peregrine Pharma/Tumor Agent: Sees Human Trials In `04
Tue, Sep 30 - 1:12pm ET - Dow Jones Business News
• Peregrine`s Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At Angiogenesis Conference
Tue, Sep 30 - 12:04pm ET - PR Newswire
Thu, Sep 18, 2003
• Peregrine Pharmaceuticals Financials
Thu, Sep 18 - 10:02am ET - EDGAR Online Financials
• Targeted Delivery of Tissue Factor Research Published in `Cancer Research`
Die letzten PR-Headlines waren von der faschen Fa.,
hier die von VION:
• Vion Pharma in License Pact With Beijing Pason
Tue 11:02am - Dow Jones Business News
• Vion Licenses Triapine(R) Rights in China, Taiwan, Hong Kong and Macao
Tue 8:45am - PR Newswire
• Vion to Present at Rodman & Renshaw Healthcare Conference
Thu, Oct 16 - PR Newswire
• Vion Pharma Gets Government Grant for Triapine Studies
Wed, Oct 1 - Dow Jones Business News
• Vion Awarded SBIR Grant for Triapine(R) Antiviral Studies
Wed, Oct 1 - PR Newswire
• VION PHARMACEUTICALS INC Files SEC form 8-K, Other Events and Financial Statements & Exhibits
Wed, Sep 10 - EDGAR Online
• Vion Enters Into Agreements for $11.3 Million Private Placement
Tue, Sep 9 - PR Newswire
• Vion and Lilly Enter Into Research Services Agreement
Mon, Sep 8 - PR Newswire
http://finance.yahoo.com/q?s=vion
hier die von VION:
• Vion Pharma in License Pact With Beijing Pason
Tue 11:02am - Dow Jones Business News
• Vion Licenses Triapine(R) Rights in China, Taiwan, Hong Kong and Macao
Tue 8:45am - PR Newswire
• Vion to Present at Rodman & Renshaw Healthcare Conference
Thu, Oct 16 - PR Newswire
• Vion Pharma Gets Government Grant for Triapine Studies
Wed, Oct 1 - Dow Jones Business News
• Vion Awarded SBIR Grant for Triapine(R) Antiviral Studies
Wed, Oct 1 - PR Newswire
• VION PHARMACEUTICALS INC Files SEC form 8-K, Other Events and Financial Statements & Exhibits
Wed, Sep 10 - EDGAR Online
• Vion Enters Into Agreements for $11.3 Million Private Placement
Tue, Sep 9 - PR Newswire
• Vion and Lilly Enter Into Research Services Agreement
Mon, Sep 8 - PR Newswire
http://finance.yahoo.com/q?s=vion
Es wird spannend zu sehen, wie die Amis heute eröffnen, evtl. bei $2.05, entweder hält die $2 Marke, das wäre gut, wenn nicht ...
Anpsnten mal sehen ob noch was nachkommt an PRs.
Anpsnten mal sehen ob noch was nachkommt an PRs.
Trading Spotlight
Jo abgeschmiert ... dann kann man ja mal ein paar ordern, wenn das Ding von der unteren Trendlinie bzw. 38-Tage Linie abprallt.
... hat ein bischen gedautert, aber ... GEHT DOCH !
ja,
es läuft schon hoch, weiter so!!!
otto33
es läuft schon hoch, weiter so!!!
otto33
Ich weiss gar nicht, warum hier so wenig los ist, seit Dez. hat sich das Ding bald verdreifacht ... oder so ...
Congratulation an den thread Eröffner,das war ein Super Tipp!
Ganz klar Daumen hoch und ich wünsche Dir weiter viel Erfolg.
greetz lucky
Ganz klar Daumen hoch und ich wünsche Dir weiter viel Erfolg.
greetz lucky
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 186 | ||
| 81 | ||
| 73 | ||
| 69 | ||
| 66 | ||
| 47 | ||
| 47 | ||
| 42 | ||
| 39 | ||
| 38 |
| Wertpapier | Beiträge | |
|---|---|---|
| 30 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 23 | ||
| 22 | ||
| 21 | ||
| 18 | ||
| 18 | ||
| 17 |
